Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women
Sra, Manraj, Glaeser‐Khan, Samira , Moshashaian‐Asl, Ranya, Cuker, Adam , Goshua, George , Goshua, George , Wang, Daniel , Sra, Manraj, Wang, Daniel Y. , Ito, Satoko

Mayo Clinic

American Journal of Hematology | April 16, 2025 | Volume: 100 | Issue: 7 | Pages: 1132-1140

10.1002/ajh.27686 | PMID 40235279 Get It

ABSTRACT Iron deficiency (ID) is a top five leading cause of disability‐adjusted life‐years in women of reproductive age around the world. Despite its enormous health burden, no screening guidelines exist for the detection and treatment of ID in women of reproductive age. We sought to determine the cost‐effectiveness of screening versus no screening for ID in women of reproductive age in the United States. A lifetime simulation of women of reproductive age was conducted using a Markov cohort model under three strategies: (1) no screening, (2) screening at a ferritin threshold of 15 μg/L, and (3) screening at a ferritin threshold of 25 μg/L, from the US health system perspective, and at a willingness‐to‐pay threshold of $100 000/quality‐adjusted life year (QALY). Epidemiologically informed ID prevalence estimates sourced from the National Health and Nutrition Examination Survey were employed for model parameterization. The primary outcome was the incremental cost‐effectiveness ratio (ICER, in $/QALY). Base‐case results for the three strategies accrued $209 700, $210 200, and $210 200 discounted lifetime costs and 23.6, 24.0, and 24.4 discounted lifetime QALYs, respectively. Screening at a ferritin threshold of 25 μg/L was the cost‐effective intervention with an ICER of $680/QALY (95% credible interval $350–$750/QALY). In dual base‐case analyses examining intravenous rather than oral iron repletion for treatment, screening at a ferritin threshold of 25 μg/L remained the cost‐effective intervention with an ICER of $2300/QALY (95% CI $1800–$3800/QALY). In probabilistic sensitivity analyses, screening at a ferritin threshold of 25 μg/L was the cost‐effective intervention in 100% of 10 000 second order Monte Carlo iterations.
The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation
Wang, Guoqiao , Li, Yan, Xiong, Chengjie , Cao, Yuchen , Blennow, Kaj, Dage, Jeffrey L. , Jack, Clifford R. , Shaw, Leslie M. , Initiative, the Alzheimer's Disease Neuroimaging, Bateman, Randall J., Wang, Guoqiao , Jack, Clifford R , Dage, Jeffrey L , Li, Yan , Xiong, Chengjie , Cao, Yuchen, Schindler, Suzanne E. , McDade, Eric , Blennow, Kaj , Hansson, Oskar , Teunissen, Charlotte E. , Zetterberg, Henrik , Ibanez, Laura , Timsina, Jigyasha , Cruchaga, Carlos , Initiative, the Alzheimer's Disease Neuroimaging, Bateman, Randall J.

Mayo Clinic

Alzheimer's & Dementia | April 16, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14587 | PMID 40235082 Get It

Abstract INTRODUCTION Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging. METHODS To address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts. RESULTS CentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages. CentiMarkers make the treatment effect more comparable than their original scales across various biomarkers. DISCUSSION The versatility of CentiMarkers makes it a valuable tool for standardized biomarker comparison in AD research, enabling informed cross‐study comparisons and contributing to accelerated therapeutic development. Adoption of the CentiMarker scale could enhance biomarker reporting and advance our understanding of AD. Highlights Comparing fluid biomarkers without appreciating their magnitude relative to the disease can be challenging. We propose a CentiMarker metric to standardize biomarker measures from normal (0) and nearly maximum abnormal AD (100) ranges. CentiMarkers make the treatment effect more comparable across various biomarkers than when using the original scales.
p16, COX-2, and Ki67 Protein Expression in DCIS and Risk of Ipsilateral Invasive Breast Cancer
Rohan, Thomas E. , Zhang, Chenxin , Wang, Yihong , Couch, Fergus J. , Greenlee, Robert T. , Honda, Stacey , Stark, Azadeh , White, Larissa L. , Chitale, Dhananjay , Xue, Xiaonan , Ginsberg, Mindy , Loudig, Olivier , Wang, Yihong , Couch, Fergus J. , Chitale, Dhananjay A , Loudig, Olivier

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 14, 2025 | Volume: 34 | Issue: 6 | Pages: 1036-1039

10.1158/1055-9965.epi-25-0143 | PMID 40227115 Get It

Abstract Background: Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with the risk of subsequent ipsilateral invasive breast cancer (IBC) is limited. Methods: In a case–control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n = 146) and on matched subjects who did not develop IBC (controls; n = 273). Conditional logistic regression was used to estimate ORs and 95% confidence intervals for the associations between immunopositivity for p16, COX-2, and Ki67 and the risk of subsequent ipsilateral IBC. Results: There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, and a risk of ipsilateral IBC. Compared with all other groups, the multivariable OR (95% confidence interval) for women who were triple positive for the three markers was 1.16 (0.38–3.54). Conclusions: p16, COX-2, and Ki67 immunopositivity was not associated with altered risk of ipsilateral IBC in women with DCIS. Impact: p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.
GLIM consensus approach to diagnosis of malnutrition: A 5‐year update
Jensen, Gordon L. , Cederholm, Tommy , Correia, María Isabel Toulson Davisson , González, Marı́a Cristina , Fukushima, Ryoji , Pisprasert, Veeradej , Cárdenas, Diana , Carrasco, Fernando , Cruz‐Jentoft, Alfonso J. , Cuerda, Cristina , Evans, David C. , Hasse, Jeanette M. , Hiki, Naoki, Jahit, Mohammad Shukri , Jáquez, Anayanet , Muscaritoli, Maurizio , Ng, Doris Hui Lan , Nyulasi, Ibolya , Pirlich, Matthias , Siltharm, S., Yu, Jianchun , Gossum, A. Van , Winkler, Marion F. , Compher, Charlene , Barazzoni, Rocco , Gautier, Juan B Ochoa , Gonzalez, M Cristina , Blaauw, Renee , Braz, Diana Cardenas , Carrasco, Fernando , Evans, David C , Fuchs-Tarlovsky, Vanessa , Gramlich, Leah , Hasse, Jeanette M , Hiesmayr, Michael , Jager-Wittenaar, Harriët , Jahit, Shukri , Jáquez, Anayanet , Keller, Heather , Malone, Ainsley , Mogensen, Kris M , Mundi, Manpreet S , Muscaritoli, Maurizio , Ng, Doris , Nyulasi, Ibolya , Schneider, Stephane , de van der Schueren, Marian , Singer, Pierre , Tappenden, Kelly A , Yu, Jianchun , Wang, Jaw-Yuan , Winkler, Marion F , Compher, Charlene , Gramlich, Leah , Shi, Han Ping , Kłęk, Stanisław , Malone, Ainsley , Mogensen, Kris M. , Mori, Naoharu , Mundi, Manpreet S. , Steiber, Alison

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | April 14, 2025 | Volume: 49 | Issue: 4 | Pages: 414-427

10.1002/jpen.2756 | PMID 40223699 Get It

Abstract Background The Global Leadership Initiative on Malnutrition (GLIM) introduced an approach for malnutrition diagnosis in 2019 that comprised screening followed by assessment of three phenotypic criteria (weight loss, low body mass index [BMI], and low muscle mass) and two etiologic criteria (reduced food intake/assimilation and inflammation/disease burden). This planned update reconsiders the GLIM framework based on published knowledge and experience over the past 5 years. Methods A working group ( n = 43 members) conducted a literature search spanning 2019–2024 using the keywords “Global Leadership Initiative on Malnutrition or GLIM.” Prior GLIM guidance activities for using the criteria on muscle mass and inflammation were reviewed. Successive rounds of revision and review were used to achieve consensus. Results More than 400 scientific reports were published in peer‐reviewed journals, forming the basis of 10 systematic reviews, some including meta‐analyses of GLIM validity that indicate strong construct and predictive validity. Limitations and future priorities are discussed. Working group findings suggest that assessment of low muscle mass should be guided by experience and available technological resources. Clinical judgment may suffice to evaluate the inflammation/disease burden etiologic criterion. No revisions of the weight loss, low BMI, or reduced food intake/assimilation criteria are suggested. After two rounds of review and revision, the working group secured 100% agreement with the conclusions reported in the 5‐year update. Conclusion Ongoing initiatives target priorities that include malnutrition risk screening procedures, GLIM adaptation to the intensive care setting, assessment in support of the reduced food intake/assimilation criterion, and determination of malnutrition in obesity.
CD27 and ICOS as targets of PD-1/PD-L1 signaling to regulate resident memory CD8+ T cells mediated pulmonary protection and pathology
Chen, Yuanyuan , Pan, Tao , Pan, Jianli, Zhao, Sheng , Shang, Ting , Xu, Hong’en , Lv, Xing , Kang, Fei , Zhao, Feng , Wang, Zheng , Wang, Zhenzhen , Song, Liqiang , Zhang, Hang , Li, Jing , Nie, Yongzhan , Shi, Lei

Mayo Clinic

No container title available | April 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6316326/v1 Get It

Abstract While tissue-resident memory CD8+ T cells (TRM cells) provide superior frontline defense against pathogens, the molecular mechanisms governing their persistence and functional regulation remain poorly defined. Our study reveals that the costimulatory receptors CD27 and ICOS coordinately sustain PD-1high CD8+ TRM cell populations following resolution of acute influenza infection. These costimulatory signals serve as critical targets for PD-1/PD-L1 blockade, thereby facilitating the rejuvenation of PD-1high TRM cells and influencing the progression of fibrotic sequelae during the memory phase. Mechanistic dissection identifies the nuclear receptor Nur77 (NR4A1) as the convergent transcriptional hub downstream of CD27/ICOS, governing proliferative renewal and maintenance of PD-1high TRM cells. Therapeutic administration of a CD27 agonist not only amplified this TRM cell subset in late-stage memory but also conferred cross-protective immunity against heterosubtypic viral challenges. Clinically, the expression of CD27 and ICOS is enriched in CD8+ T cells within the lung tissues of patients with pulmonary fibrosis. Collectively, our findings establish the "CD27/ICOS-NR4A1-Proliferation" axis as a linchpin of PD-1/PD-L1-mediated TRM cell homeostasis, revealing druggable targets for intercepting infection-associated fibrotic progression.
Interpretation of guidelines for diagnosis and treatment of ovarian cancer with integrated traditional Chinese and western medicine
Liu, Jiaxin , Cui, Yongjia, Lü, Wenping , Zhuo, Zhili , Cui, Yongjia , Wang, Jianliu , Yang, Lin

Mayo Clinic

Guidelines and Standards of Chinese Medicine | April 9, 2025 | Volume: 3 | Issue: 2 | Pages: 178-186

10.1097/gscm.0000000000000061 Get It

Ovarian cancer (OC) has the highest mortality rate among gynecologic malignant tumors and is clinically difficult to cure. Traditional Chinese medicine (TCM) has shown unique advantages in the treatment of OC. However, there is currently a lack of normative guidance documents for the treatment of OC with integrated traditional Chinese and western medicine. The guidelines are the first comprehensive approach to diagnosing and treating OC by integrating TCM with western medicine. Adhering to evidence-based principles, the guidelines draw on the most recent advancements in OC treatment from both domestic and international researches. The guidelines formulate a variety of therapeutic methods, including oral Chinese herbal medicine, acupuncture, and external treatments, providing a treatment strategy for the combined use of TCM and western medicine in OC. Furthermore, the guidelines establish a diagnostic and treatment pathway for the holistic management of OC with TCM throughout the disease’s progression. The guidelines were officially published in the China Association of Chinese Medicine in January 2023, which provided a scientific basis for the formulation of clinical diagnosis and treatment strategies and promoted integration with international academic standards. This paper interpreted the features of the guidelines and the 7 PICO issues (Population, Intervention, Comparison, Outcome) in the whole TCM management of OC, aiming to help TCM and western medicine practitioners better understand and apply the guidelines, and provide better medical services for patients with OC.
Medical Therapy Versus Percutaneous Coronary Intervention in Patients with Myocardial Bridging from a National Population-Based Cohort Study: The Use of Big Data Analytics
Krittanawong, Chayakrit , Padilla, Ferran , Qadeer, Yusuf Kamran , Wang, Zhen , Sharma, Samin K. , Lavie, Carl J., Schaff, Hartzell V. , Schwarz, Ernst R. , Sharma, Samin K , Schaff, Hartzell , Ang, Song Peng , Gaibazzi, Nicola , Lavie, Carl J.

Mayo Clinic

Cardiogenetics | April 9, 2025 | Volume: 15 | Issue: 2 | Pages: 10

10.3390/cardiogenetics15020010 Get It

Myocardial Bridging (MB) is typically a benign congenital coronary anomaly. MB can infrequently result in complications such as myocardial ischemia, arrhythmias, and sudden cardiac death. Recent studies suggest an underlying genetic component for MB involving DES, FBN1, SCN2B, or NOTCH1. The role of percutaneous coronary intervention (PCI) in managing MB, compared to optimal medical therapy (OMT), remains uncertain. Our study used the National Inpatient Sample (NIS) Database to identify patients aged 18 or older with myocardial bridging who were managed with PCI versus medical therapy. We compared the outcomes between both groups including in-hospital mortality, the trend of management of MB and other in-hospital outcomes or complications. Our results showed no statistically significant difference between both subgroups when comparing in-hospital mortality and secondary outcomes of cardiac arrest and the development of an acute kidney injury (AKI). Patients with myocardial bridging treated with PCI had a higher risk of developing cardiogenic shock, requiring LVAD, and requiring the use of intra-aortic balloon pump (IABP) compared to the medical therapy subgroup. Our study suggests the decision to perform PCI in myocardial bridging patients should be individualized such as in patients with refractory symptoms despite medical therapy or those with known high-risk features.
BMJ Innovations roundtable: innovations that will have the biggest impact on orthopaedics over the next decade
Liu, Yajun , Wyles, Cody, Li, Weishi , Luo, Yangyu, Goldberg, A. , Ren, Ling , Zou, Xuenong, Jiang, Xieyuan, Tsoi, Kelvin , Wang, Junqiang , Muschler, George F. , Wyles, Cody C. , Luo, Yangyu, Xiong, Zhuo, Goldberg, Andy, Zhou, S. Kevin , Zou, Xuenong, Jiang, Xieyuan

Mayo Clinic

BMJ Innovations | April 8, 2025 | Volume: 11 | Issue: 2 | Pages: 107-111

10.1136/bmjinnov-2025-001373 Get It

Context-Aware Optimal Transport Learning for Retinal Fundus Image Enhancement
Vasa, Vamsi Krishna, Zhu, Wenhui , Xiong, Yujian, Dumitrașcu, Oana , Qiu, Peijie , Wang, Yalin

Mayo Clinic

2025 IEEE/CVF Winter Conference on Applications of Computer Vision (WACV) | April 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: 4016-4025

10.1109/wacv61041.2025.00395 | PMID 40791801 Get It